CD274 and non-small cell lung carcinoma: Previous clinical studies containing advanced NSCLC patients demonstrated that PD-L1 expression evaluated by TPS or CPS usually distributes as one third in the TPS < 1% group, one third in the 1% to 49% group, and one third in the ≥50% group [39,40].